Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention

Current Atherosclerosis Reports

Volumn 12, Issue 1, 2010, Pages 8-10

  Clearfield, Michael ^a  

^a Touro University California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TROPONIN I;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; CORONARY STENT; DRUG MEGADOSE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; RISK REDUCTION; STABLE ANGINA PECTORIS; STRESS ECHOCARDIOGRAPHY; UNSTABLE ANGINA PECTORIS;

EID: 77149147760     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0083-x     Document Type: Note

References (10)

1. Pasceri V, Patti G, Nusca A, et al.: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA study. Circulation 2004, 110:674-678.
2. Patti G, Pasceri V, Colonna G, et al.: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007, 49:1272-1278.
3. Athyros VG, Kakafika AI, Tziomalos K, et al.: Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009, 15:479-489.
4. Veselka J, Zemanek D, Hajek K, et al.: Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single center, prospective and randomized study. Am J Cardiol 2009, 104:630-633.
5. Patti G, Chello M, Pasceri V, et al.: Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs substudy. J Am Coll Cardiol 2006, 48:1560-1566.
6. Dimmeler S, ASicher A, Vasa M, et al.: HMG-CoA reductase inhibitors increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest 2001, 108:391-397.
7. Liu PY, Liu YW, Lin LJ, et al.: Evidence for statin pleiotropy in humans: Differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009, 119:131-138.
8. Sanguigni V, Pignatelli P, Lenti L, et al.: Short term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005, 111:412-419.
9. Briguori C, Visconti G, Focaccio A, et al.: Novel approaches for preventing or limiting events (NAPLES) II Trial impact of a single high loading dose of atoravastatin on periprocedural myocardial infarction. J Am Col l Cardiol 2009 Aug. 3 (Epub ahead of print).
10. Schouten O, Boersma E, Hoeks SE, et al.: Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009, 361:980-989.